A review of the NHS's £330M Federated Data Platform (FDP) — the data layer NHS England uses to coordinate elective care — tests whether Palantir, the US data software firm that runs it, should keep the contract when the February break clause opens.
The UK government has ordered a formal review of its £330 million Palantir NHS contract, a software deal that runs through the Federated Data Platform (FDP), the data layer NHS England uses to coordinate elective care and other services. The contract, awarded to the US data-software firm Palantir under a software-as-a-service model with partner firms, includes a break clause that fires in February, giving Labour a rare procurement lever. Palantir says the FDP has helped the NHS see 110,078 additional patients and has shaved roughly 7% off the time it takes to answer 28-day cancer referrals. Lord Drayson, a science and technology figure, told The Register that the deal represents a failure of "standards" in UK procurement, an argument that the contract should have been used to grow a British health-tech capability rather than handed to a US vendor. The review will weigh that critique against the platform's claimed results.
The money arc behind the deal is short and sharp. Palantir was awarded a £1 contract during the pandemic to provide data tools to NHS England. It then won £60 million in uncontested deals with the NHS, and after the pandemic was awarded the £330 million FDP contract under the previous Conservative government. The February break clause, triggered by either side under defined conditions, turns the review from a talking point into a calendar item. NHS England defends the FDP award as the result of a competitive tender and says the platform is necessary to clear the post-pandemic elective care backlog.
The critique is sharpened by Palantir's history. The company was seeded with capital from In-Q-Tel, the CIA's venture arm, and has since won work with US Immigration and Customs Enforcement (ICE). Industry experts quoted in the original reporting have welcomed the review, though they are not identified by name in the source and their views should not be read as a consensus position.
The constructive question is what a fair, sovereign alternative procurement would have to deliver. A UK-built federated data platform would need to match Palantir's claimed operational numbers in a live NHS environment, win a competitive tender of its own, and survive scrutiny on data residency, security clearances, and the long-term cost of running a multi-vendor platform. The break clause in February is not an answer. It is the deadline by which someone, on one side or the other, has to decide what the next decade of NHS data infrastructure should look like.